CLINT1 is a subtype-specific biomarker and a downstream effector of p53-R273H in lung adenocarcinoma migration

• CLINT1 is specifically upregulated in LUAD but not in LUSC, at both mRNA and protein levels. • High CLINT1 expression is associated with poor overall and first-progression survival in LUAD patients. • CLINT1 acts as a downstream effector of p53-R273H, mediating its pro-migratory effects in LUAD. • Targeting CLINT1 may offer a novel therapeutic strategy for LUAD, especially in p53-R273H-mutant tumors.